Guangdong Zhongsheng Pharmaceutical
Launch date
Employees
Market cap
CAD1.8b
Enterprise valuation
CAD1.5b (Public information from Sep 2024)
Share price
CNY11.08 002317.SZ
Baoding Hebei (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.9b | 2.4b | 2.7b | 2.6b | 2.9b | 3.4b | 3.8b |
| % growth | (25 %) | 28 % | 10 % | (2 %) | 10 % | 17 % | 13 % |
| EBITDA | 487m | 539m | 541m | 512m | 480m | 614m | 705m |
| % EBITDA margin | 26 % | 22 % | 20 % | 20 % | 17 % | 18 % | 19 % |
| Profit | (427m) | 278m | 322m | 263m | 273m | 426m | 463m |
| % profit margin | (23 %) | 11 % | 12 % | 10 % | 9 % | 13 % | 12 % |
| EV / revenue | 4.7x | 3.6x | 8.2x | 5.2x | 3.3x | 2.8x | 2.5x |
| EV / EBITDA | 18.2x | 16.4x | 40.4x | 26.6x | 19.9x | 15.6x | 13.6x |
| R&D budget | 114m | 137m | 157m | 127m | - | - | - |
| R&D % of revenue | 6 % | 6 % | 6 % | 5 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
